Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis

• Published in: Zhōnghuá yùfáng-yīxué zázhì Vol. 57; no. 8; p. 1176
• Main Authors: Xu, Y, Pan, R L, Huang, H, Wang, M Z
• Format: Journal Article
• Language: Chinese
• Published: China 06.08.2023
• Subjects: Humans; Immune Checkpoint Inhibitors - adverse effects; Lung Neoplasms; Pneumonia
• ISSN: 0253-9624
• DOI: 10.3760/cma.j.cn112150-20221121-01139

The application of immune checkpoint inhibitors (ICIs) has shown impressive anti-tumor efficacy across multiple malignant tumors, leading to the prolonged survival period of tumor patients. However, immune-related adverse events should not be ignored. Checkpoint inhibitor pneumonitis (CIP) is a pulmonary adverse event that can occur in malignant tumor patients after receiving ICIs treatment. The incidence of CIP has been reported to range from 2.7% to 20.0% in clinical trials and real-world research. Furthermore, some patients might suffer from serious or fatal CIP, and the prognosis of such patients will be poor. Early detection, diagnosis and treatment may improve the prognosis of these patients. The establishment of a whole-process CIP comprehensive surveillance management mode covering the health care system and patients during ICIs treatment might be helpful to improve the early diagnosis and treatment capacity of CIP, which is a key measure to improve the prognosis of these patients.